349 related articles for article (PubMed ID: 36555391)
1. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.
Su YC; Lee WC; Wang CC; Yeh SA; Chen WH; Chen PJ
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555391
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
4. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
6. Bicarbonate transporter SLC4A7 promotes EMT and metastasis of HNSCC by activating the PI3K/AKT/mTOR signaling pathway.
Hu J; Li G; Liu Z; Ma H; Yuan W; Lu Z; Zhang D; Ling H; Zhang F; Liu Y; Liu C; Qiu Y
Mol Carcinog; 2023 May; 62(5):628-640. PubMed ID: 36727616
[TBL] [Abstract][Full Text] [Related]
7. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of the PI3K-AKT-mTOR pathway in head and neck squamous cell carcinoma: Data from Brazilian population.
Marques AEM; Borges GA; Viesi do Nascimento Filho CH; Vianna LMS; Ramos DDAR; Castilho RM; Squarize CH; Guerra ENS
Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Apr; 133(4):453-461. PubMed ID: 35153184
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
[TBL] [Abstract][Full Text] [Related]
10. Aberrant translation regulated by METTL1/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression.
Chen J; Li K; Chen J; Wang X; Ling R; Cheng M; Chen Z; Chen F; He Q; Li S; Zhang C; Jiang Y; Chen Q; Wang A; Chen D
Cancer Commun (Lond); 2022 Mar; 42(3):223-244. PubMed ID: 35179319
[TBL] [Abstract][Full Text] [Related]
11. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
12. G-Protein-Coupled Receptor Kinase-Interacting Protein 1 (GIT1) Promotes Head and Neck Squamous Cell Carcinoma Metastases via Activating the PI3K/AKT/mTOR Signal Pathway.
Xu R; Xu R; Wang Y; Wang W; Jiang L; Gong S
Comput Math Methods Med; 2022; 2022():6881932. PubMed ID: 35116073
[TBL] [Abstract][Full Text] [Related]
13. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.
Vander Broek R; Mohan S; Eytan DF; Chen Z; Van Waes C
Oral Dis; 2015 Oct; 21(7):815-25. PubMed ID: 24219320
[TBL] [Abstract][Full Text] [Related]
14. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
[TBL] [Abstract][Full Text] [Related]
15. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
[TBL] [Abstract][Full Text] [Related]
16. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.
Freudlsperger C; Burnett JR; Friedman JA; Kannabiran VR; Chen Z; Van Waes C
Expert Opin Ther Targets; 2011 Jan; 15(1):63-74. PubMed ID: 21110697
[TBL] [Abstract][Full Text] [Related]
17. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
Shorning BY; Dass MS; Smalley MJ; Pearson HB
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
[TBL] [Abstract][Full Text] [Related]
18. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
19. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
20. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Zaryouh H; De Pauw I; Baysal H; Peeters M; Vermorken JB; Lardon F; Wouters A
Med Res Rev; 2022 Jan; 42(1):112-155. PubMed ID: 33928670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
